Oncotarget

Research Papers:

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

James T. Lynch _, Robert McEwen, Claire Crafter, Ultan McDermott, Mathew J. Garnett, Simon T. Barry and Barry R. Davies

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:22128-22139. https://doi.org/10.18632/oncotarget.8031

Metrics: PDF 1864 views  |   HTML 2692 views  |   ?  


Abstract

James T. Lynch1, Robert McEwen1, Claire Crafter1, Ultan McDermott2, Mathew J. Garnett2, Simon T. Barry1, Barry R. Davies1

1Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom

2Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, United Kingdom

Correspondence to:

James T. Lynch, e-mail: [email protected]

Keywords: PI3K, AKT, mTOR, Notch, leukemia

Received: November 16, 2015     Accepted: February 18, 2016     Published: March 10, 2016

ABSTRACT

Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify tumor types that are sensitive to PI3K pathway inhibitors we screened compounds targeting PI3Kα/δ (AZD8835), PI3Kβ/δ (AZD8186), AKT (AZD5363) and mTORC1/2 (AZD2014) against a cancer cell line panel (971 cell lines). There was an enrichment of hematological malignancies that were sensitive to AKT and mTOR inhibition, with the greatest degree of sensitivity observed in T-cell acute lymphoblastic leukemia (T-ALL). We found that all NOTCH mutant T-ALL cell lines were sensitive to AKT and mTORC1/2 inhibitors, with only partial sensitivity to agents that target the PI3K α, β or δ isoforms. Induction of apoptosis only occurred following AKTi treatment in cell lines with PTEN protein loss and high levels of active AKT. In summary, we have demonstrated that T-ALL cell lines show differential sensitivity to inhibition at different nodes in the PI3K/AKT/mTOR pathway and inhibiting AKT or mTOR may have a therapeutic benefit in this disease setting.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8031